RxDoctor Payments Data

Nathan Stice, MD

Obstetrics & Gynecology · Bowling Green, KYNPI 1639213044

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $189,055 of the $199,485 with a category attached, or 94.8%. Organon accounts for 68.6% of it on its own, with 44 other manufacturers making up the rest. Among obstetrics & gynecology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$199,485in general payments, 2019–2025

Across 498 payments — averaging $400.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organon$137K
  • Merck$35K
  • Astellas Pharma US Inc$23K
  • Aspira Women's Health Inc$995
  • AbbVie$967
  • Mayne Pharma Commercial LLC$268
  • plus $3K from 39 others

What the payments were for

  • Speaking & faculty fees$189,05595%
  • Travel & lodging$4,0042%
  • Food & beverage$6,1433%
  • Education$2830%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$199,485 in reported general payments places this provider in the 95th percentile of 474 obstetrics & gynecology providers in Kentucky.

See all obstetrics & gynecology providers in Kentucky

Medicare billing

Part B allowed, 2024
$71,445
Medicare patients
139
Services billed
3,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron27$15,407
ElmironPentosan Polysulfate Sodium11$6,864
Estradiol100$6,097
Estradiol (Twice Weekly)Estradiol25$3,195
DottiEstradiol11$1,228
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$468
ProgesteroneProgesterone, Micronized20$417
Clobetasol Propionate19$366
Fluconazole22$78
Trazodone Hcl17$69
Metronidazole11$43
Zolpidem Tartrate12$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$22,787$15,40727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 obstetrics & gynecology providers in Kentucky.

Other obstetrics & gynecology in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →